Discovery of amivantamab (JNJ-61186372), a bispecific antibody …
网页The crystal structure of the anti-MET Fab of amivantamab bound to MET was solved, and the interaction between the two molecules in atomic details was elucidated. Amivantamab antagonized the hepatocyte growth factor (HGF)-induced signaling by binding to MET Sema domain and thereby blocking HGF β-chain-Sema engagement.
Discovery of amivantamab (JNJ-61186372), a bispecific …
网页2021年1月1日 · The crystal structure of the MET B Fab arm of amivantamab bound to human MET Sema-PSI region was solved to better understand the potent inhibition of MET signaling. The structure of the Fab–Sema-PSI complex was determined to 3.1-Å resolution with one complex in the P4 3 2 1 2 asymmetric unit ( Table S4 ).
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet …
网页2020年10月2日 · Amivantamab (JNJ-61186372) is an anti-EGFR and anti-cMet bispecific low fucose antibody with enhanced Fc function designed to treat tumors driven by activated EGFR and/or cMet signaling.
Amivantamab efficacy in wild-type EGFR NSCLC tumors …
网页2024年9月6日 · Amivantamab efficacy has been demonstrated to be linked to three mechanisms of action (MOA): immune cell-mediated killing, receptor internalization and degradation, and inhibition of ligand...
Amivantamab: Uses, Interactions, Mechanism of Action
网页2021年5月22日 · Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved ...
The development of amivantamab for the treatment of non-small …
网页2023年10月25日 · In this review, we discuss the unique structure, pharmacodynamics, and pharmacokinetics of amivantamab as well as its indication towards EGFR exon20ins and beyond, focusing on dual inhibition of EGFR and MET, which could be employed for the treatment of MET-altered tumors as well as those with sensitizing EGFR mutations who have progressed on ...
Amivantamab in the Treatment of Metastatic NSCLC: Patient …
网页2022年10月12日 · Antibody Bispecific Structure. Amivantamab (JNJ-61186372) is a fully human monoclonal antibody with bispecific binding: one portion of its antigen-binding fragment (FAB) recognizes the epidermal growth factor receptor (EGFR), while the other one recognizes the MET proto-oncogene (MET) (Figure 1).
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and …
网页2023年3月1日 · Amivantamab is a fully human Fc-active immunoglobulin G1 (IgG1) bispecific antibody with high affinity (K D) binding to both EGFR (1.4 nanomolar/liter) and MET (K D of 40 picomolar/liter). 21, 22 Amivantamab targets the extracellular domains of EGFR and MET, leading to inhibition of both pathways independent of …
FDA Approval Summary: Amivantamab for the Treatment of
网页2023年9月1日 · The FDA granted accelerated approval for amivantamab-vmjw (hereafter referred to as amivantamab), a bispecific antibody directed against EGFR and mesenchymal-epithelial transition receptor, on May 21, 2021, for the treatment of adult patients with locally advanced or metastatic non-small cell lung c ….
Amivantamab: First Approval | Drugs - Springer
网页2021年7月22日 · Amivantamab (amivantamab-vmjw; Rybrevant™) is a fully human bispecific monoclonal antibody directed against epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET) [1]. It is being developed by Janssen Biotech, using Genmab’s DuoBody ® technology, for the treatment of non-small cell lung cancer (NSCLC).
跳至内容